1. Martin-Carbonero L, Soriano V, Valencia E, et al. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV infected patients. AIDS Res Hum Retroviruses 2001;17:1467-171.
  2. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-7.
  3. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001;33:240-7.
  4. Smit C, van den Berg C, Geskus R, et al. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr 2008;47:221-5.
  5. Van de Laar TJW, van der Bij AK, Prins M, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007;196:230-8.
  6. Danta M, Brown D, Bhagani S, et al; HIV and Acute HCV (HAAC) group. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007;21:983-91.
  7. Crofts N, Aitken CK, Kaldor JM. The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not. Med J Aust 1999;170:220-1.
  8. Sasadeusz J. Human immunodeficiency virus-hepatitis C  co-infection: swapping new problems for newer ones. Intern Med J 2001;31:418-21.
  9. Bodsworth NJ, Cunningham P, Kaldor J, et al. Hepatitis C virus infection in a large cohort of homosexually active men: independent associations with HIV-1 infection and injecting drug use but not sexual behaviour. Genitourin Med 1996;72:118-22.
  10. Petoumenos K, Ringland C; Australian HIVOD. Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database. HIV Med 2005;6:155-63.
  11. Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C virus prevalence among patients infected with human immunodefi ciency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002;34:831-7.
  12. Maheshwari A, Thuluvath PJ. Management of acute hepatitis C. Clin Liver Dis 2010;14:169–76.
  13. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-9.
  14. Grebel J, Raffa JD, Lai C, et al. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol 2007;21:447–51.
  15. Grebely J, Raff a JD, Lai C, Krajden M, Conway B, Tyndall MW. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Canadian Journal of Gastroenterology 2007;21:447-51.
  16. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
  17. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34:809-16.
  18. Sanchez-Quijano A, Andreu J, Gavilan F, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995;14:949-53.
  19. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5.
  20. Eyster ME, Diamondstone LS, Lien JM, et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of co-infection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. AIDS 1993;6:602-10.
  21. Garcia-Samaniego J, Rodriguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001;96:179-83.
  22. Rockstroh JK, Spengler U, Sudhop T, et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996;91:2563-8.
  23. Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001;183:134-7.
  24. Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/ hepatitis C virus-co-infected adults. AIDS 2007;21:2209-16.
  25. Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the eff ect of  co-infection on survival. Clin Infect Dis 1999;29:150-4.
  26. Rutschmann OT, Negro F, Hirschel B, et al. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV.J Infect Dis 1998;177:783-5.
  27. Perez-Olmeda M, Garcia-Samaniego J, Soriano V. Hepatitis C viraemia in HIV-HCV coinfected patients having immune restoration with highly active antiretroviral therapy. AIDS 2000;14:212.
  28. Fialaire P, Payan C, Vitour D, et al. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection. J Infect Dis 1999;180:574-5.
  29. Cribier B, Rey D, Schmitt C, et al. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995;9:1131-6.
  30. Hernandez MD, Sherman KE. HIV/Hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS 2011;6:478-82.
  31. Bruno R, Sacchi P, Puoti M, et al. Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. J Acquir Immune Defic Syndr 2007;46:297-303.
  32. Alvarez D, Dieterich DT, Brau N, et al. Zidovudine use but not weight‐based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. 2006;13:683-9
  33. Nelson M, Amaya G, Clumeck N, , et al; ECHO and THRIVE Study Groups. Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. J Antimicrob Chemother 2012;67:2020-8.
  34. Clotet B, Clumeck N, Katlama C,et al. Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials. J Antimicrob Chemother 2010;65:2450-4.
  35. John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998;12:2289-93.
  36. McGovern BH, Birch C, Zaman MT, et al. Managing symptomatic drug-induced liver injury in HIV hepatitis C virus-coinfected patients: a role for interferon. Clin Infect Dis 2007;45:1386-92.
  37. Labarga P, Soriano V, Vispo ME, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007;196:670-6.
  38. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatology 2014;60:392-420.
  39. Scott DR, Levy MT. Liver transient elastography (Fibroscan® ): a place in the management algorithms of chronic viral hepatitis. Antivir Ther2010;15:1-11.
  40. The Australian Commentary to the US DHHS Guidelines for the use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents has been prepared by the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) Sub-Committee for Guidance on HIV Management in Australia, 2016
  41. Hepatitis C Virus Infection Consensus Statement Working Group. Australian recommendations for the management of hepatitis C virus infection: a consensus statement (January 2017). Melbourne: Gastroenterological Society of Australia, 2017.